
    
      METHOD: Fourteen patients with a DSM-IV diagnosis of treatment resistant OCD, under stable
      treatment with SSRI's and neuroleptic augmentation will enter an 12-week single blind trial
      of ondansetron initiated at a dose of 0.25 mg twice daily for 6 weeks, that will be titrated
      to 0.5 mg twice daily for 6 weeks.
    
  